Research Institute

Phase III Study Comparing Gedatolisib + Palbociclib & Fulvestrant to SOC treatments in Breast Ca

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeWythevilleSalem

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy 

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05501886?term=Gedatolisib+in+Combination+with+Palbociclib+and+Fulvestrant&draw=2&rank=4